-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Meikang Biotech Co., Ltd. ("Meikang Bio" or "Company") issues no more than 103,590,786 shares to no more than 35 specific subjects, raising a total of not more than $60,000.00 million. After deducting the issuance expenses, it is intended to be used for in-patient diagnostic product development and industrialization projects, information system upgrade projects and repayment of bank loans.The company is mainly engaged in the research and development, production and marketing of in-body diagnostic products, as well as in-body diagnostic products agency business, and provide third-party medical diagnostic services; The main suppliers are well-known companies in this category, including Abbott, Siemens, Hitachi and Hessen Meikang and other international first-class out-of-body diagnostic manufacturers.According to World Preview 2018, Outlook to 2024 released by Evaluate MedTech, global medical device market sales in 2017 were $405.00 billion, up 4.60% YoY; According to the China Medical Device Blue Book (2019 edition) published by the Institute of Medical Research, the market size of China's in-body diagnostic industry in 2018 was approximately 60.400 billion yuan, up 18.43% YoY from 2017. (Sina Pharmaceutical News
)